MIMETAS announces the opening of a brand-new office and laboratory in Gaithersburg, MD, USA. The new location provides MIMETAS with capacity for further growth in the USA and to strengthen local customer support, product development and sales of the OrganoPlate®, a versatile, high-throughput 3D microfluidic cell culture device.


Date And Time: Tue, April 16, 2019, 1:00 PM – 5:30 PM EDT

Location: Science and Engineering Hall, Lehman Auditorium, 800 22nd Street NW, Lower Level, Washington, DC 20052

The George Washington University and the Technology Commercialization Office are pleased to invite you to the 2019 Innovation Competition!

The Technology Commercialization Office (TCO) is showcasing promising and impactful GW research with commercial potential. This event provides a forum for idea sharing between GW researchers, entrepreneurs, and members of the venture community, as well as the opportunity to present technologies available for licensing to a panel of experienced entrepreneurs, investors, and industry professionals. Finalists will pitch their technologies for a chance to win $30,000 in prizes!


As head of the FDA, Scott Gottlieb has been outspoken about drug pricing, chiming in on an area that is typically tangential to the agency commissioner’s purview. In the first announcement of his next steps — made one day before he’s scheduled to officially end his shorter-than-expected tenure — Gottlieb says he’s returning to the American Enterprise Institute as a resident fellow focused on these exact issues.

BHCR logo 500

Scientists, engineers, life science executives, academics, government officials and other constituents recently gathered to discuss the state of the BioHealth Capital Region (BHCR) at the annual Mid Atlantic Science & Technology (MAST) Showcase, hosted by the International Society for Pharmaceutical Engineering – Chesapeake Bay Area Chapter’s (ISPE-CBA).


June 2 - 3, 2019

Held in advance of the BIO International Convention, at AURP’s BIO Health Caucus, we will explore trends in life science research, funding resources, the marriage of life science and engineering in global partnership opportunities. Discover the unique roles that biomedical innovation districts and research parks play in innovation ecosystems in the U.S. and around the globe. Translating discoveries from the laboratory to the market has never been more important.


Pharm-Olam, a global, midsized CRO offering full-service clinical development solutions for oncology, infectious diseases and vaccines, and rare and orphan diseases, has been named a winner in Life Science Leader magazine’s 2019 CRO Leadership Awards.


Immunomic Therapeutics, Inc. will present late-breaking preclinical data which shows that its’ investigational nucleic acid platform, UNITE, may enhance antitumor immunity when used in connection with its investigational DNA vaccine, ITI-7000. In preclinical studies, ITI-7000, an investigational DNA vaccine targeting ErbB2/HER2, demonstrated robust activation of known anti-tumor CD4 and CD8 cells in vivo and promoted tumor infiltration with activated CD8 T cells. These data will be presented at the American Association for Cancer Research (AACR) 2019 meeting in Atlanta, Georgia.


A sampling of recent reports shows just how much immuno-oncology continues to grow. Last month, GrandView Research projected a more than doubling of the global cancer immunotherapy market, from the $58.1 billion it tallied in 2018, to $126.9 billion by 2026. As GEN noted when it ranked the top immuno-oncology startups in February, market projections range from $124.88 billion (Transparency Market Research) to $173 billion (Market Research Engine) by 2024.


Emmes today announced that it provided the data management support for a study, funded by the National Institutes of Health (NIH) and approved by the Food and Drug Administration (FDA), to safely use Acyclovir to treat infants infected with the Herpes Simplex Virus. Acyclovir, known by the brand name Zovirax, now includes recommended usage and dosage for newborns and infants up to three months of age on its label.


CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. pharmaceutical company with a platform to develop and accelerate the launch of pharmaceutical products and innovative therapeutics in China, the U.S., and throughout the world, announced that Wei-Wu He, Ph.D., Executive Chairman of CASI, has been appointed Chief Executive Officer. Dr. He will continue to serve as Chairman of the Board of Directors. Dr. He succeeds Ken K. Ren, Ph.D. who for personal reasons is stepping down from his role as Chief Executive Officer but will remain on the Company’s Board of Directors.